Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Ipsen clinical trials
The registry lists 356 studies whose lead sponsor is Ipsen or one of 7 companies grouped under it. 23 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Ipsen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Ipsen.
- Ipsen288 studiesSame company
Something wrong?
- 21 studies →
- 16 studies →
- 11 studies →
- Clementia Pharmaceuticals Inc.10 studies →Acquired — became part of Ipsen, Apr 18, 2019 · source ↗
Something wrong?
- 5 studies →
- 3 studies →
- ImCheck Therapeutics, an Ipsen company2 studies →Acquired — became part of Ipsen, Dec 15, 2025 · source ↗
Something wrong?
Focus areas
Conditions Ipsen leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 356. Browse all 356 →
- A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)RecruitingNCT06089616
- A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisRecruitingNCT06016842Phase 3
- A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentRecruitingNCT06850038
- Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or LactationRecruitingNCT06258902
- A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in ChinaRecruitingNCT07588880
- A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South KoreaRecruitingNCT07185919
- A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentRecruitingNCT07585097
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingNCT07387549Phase 3
- Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During PregnancyRecruitingNCT07556913
- Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentRecruitingNCT07314164
- A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursRecruitingNCT07213817Phase 1/2
- A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the EyebrowsRecruitingNCT07779252Phase 3
- A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive ChemotherapyNot yet recruitingNCT07623187Phase 2/3
- A Study of IPN10200 for the Treatment of Cervical Dystonia in AdultsRecruitingNCT06937931Phase 2
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor TherapiesRecruitingNCT07213830Phase 1/2
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.RecruitingNCT04752774Phase 1/2
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibRecruitingNCT06479135Phase 3
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerRecruitingNCT05797831Phase 2/3
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentRecruitingNCT03662126Phase 2/3
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingNCT03787602Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFRecruitingNCT04640532Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingNCT04878003Phase 2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaRecruitingNCT04835584Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeActive, not recruitingNCT05035030Phase 3
Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen
- A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.Active, not recruitingNCT05627362Phase 2
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaActive, not recruitingNCT05426733Phase 3
Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen
- A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing TreatmentActive, not recruitingNCT06447168
- A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)Active, not recruitingNCT06730061Phase 3
- Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)Active, not recruitingNCT07497724
- Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICCompletedNCT03659916Phase 3
Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Active, not recruitingNCT04526665Phase 3
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial LinesActive, not recruitingNCT04821089Phase 1/2
- Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsCompletedNCT03945773Phase 2
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Phase 3
Sponsor listed in the registry: Epizyme, Inc. · First submitted before Epizyme, Inc. became part of Ipsen
- A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain TumoursActive, not recruitingNCT07441707Phase 1
- A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsActive, not recruitingNCT07435428Phase 3
- Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)Active, not recruitingNCT04106349
- Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Active, not recruitingNCT03647878
- A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid TumoursActive, not recruitingNCT06833008Phase 1/2
- A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursActive, not recruitingNCT06305247Phase 1/2
- CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb SpasticityActive, not recruitingNCT06245772
- A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsActive, not recruitingNCT07427797Phase 3
- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsActive, not recruitingNCT06625060Phase 2
- First-in-Human Study of ICT01 in Patients With Advanced CancerActive, not recruitingNCT04243499Phase 1/2
Sponsor listed in the registry: ImCheck Therapeutics, an Ipsen company · First submitted before ImCheck Therapeutics became part of Ipsen
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsActive, not recruitingNCT06047444Phase 3
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsActive, not recruitingNCT06047457Phase 3
- A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its DevelopmentActive, not recruitingNCT06055725
- A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in SpainCompletedNCT07191704
- Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid TumorsTerminatedNCT05307874Phase 1/2
Sponsor listed in the registry: ImCheck Therapeutics, an Ipsen company · First submitted before ImCheck Therapeutics became part of Ipsen
- Odevixibat for the Treatment of Progressive Familial Intrahepatic CholestasisNo longer availableNCT04483531
Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen